Company: APM
Filing Date: 2025-10-14
Form Type: 424B5
Source: 0001213900-25-098635
Chunk: 85

Company: Aptorum Group Ltd
Filing Date: 2025-10-14
Form: 424B5
Chunk 85
---
, and the occurrence of any of these risks might
cause you to lose all or part of your investment.

In addition to the risk factors
referenced above, we want to disclose the additional risk factors noted below.

Shares eligible for future sale may adversely affect the market price of our Class A Ordinary Shares on NASDAQ or other stock markets, as the future sale of a substantial amount of outstanding Class A Ordinary Shares in the public marketplace could reduce the price of our Class A Ordinary Shares.

The market price of our Class
A Ordinary Shares could decline as a result of sales of substantial amounts of our Class A Ordinary Shares in the public market, or the
perception that these sales could occur. In addition, these factors could make it more difficult for us to raise funds through future
offerings of our Class A Ordinary Shares. An aggregate of 13,269,528 Class A Ordinary Shares are outstanding as of the date of this
prospectus. We are including 540,540 resale shares in this prospectus. All of the Class A Ordinary Shares sold in our initial public offering
are freely transferable without restriction or further registration under the Securities Act. The remaining Class A Ordinary Shares will
be “restricted securities” as defined in Rule 144. These Class A Ordinary Shares may be sold without registration under the
Securities Act to the extent permitted by Rule 144 or other exemptions under the Securities Act.

Resales of our Class A Ordinary Shares in the public market by the Selling Shareholders may cause the market price of our Class A Ordinary Shares to decline.

Sales
of Resale Shares could result in resales of our Class A Ordinary Shares by our current shareholders concerned about the potential dilution
of their holdings. In turn, these resales could have the effect of depressing the market price for our Class A Ordinary Shares.

<div align='center'>4

USE OF PROCEEDS</div>

Except as described in any
prospectus supplement and any free writing prospectus in connection with a specific offering, we currently intend to use the net proceeds
from the sale of the securities offered under this prospectus to fund the development and commercialization of our projects and the growth
of our business, primarily working capital, and for general corporate purposes. We may also use a portion of the net proceeds to acquire
or invest in technologies, products and/or businesses that we believe will enhance the value of our Company, although we have no current
commitments or agreements with respect to any such transactions as of the date of